BioXcel Therapeutics expands immuno-oncology partnership with Nektar in pancreatic cancer
BioXcel and Nektar announced a new clinical partnership. The collaboration will evaluate the combination of BTI’s BXCL701, a small molecule immune-modulator, DPP 8/9 and FAP inhibitor; Nektar’s NKTR-214, a CD122-biased agonist; and a checkpoint inhibitor as potential therapy for pancreatic cancer. September 24, 2018